Chris Painter
Health Economist
Chris Painter’s research focuses on using health economics and health technology assessment methods to inform resource allocation policy decisions for a wide range of communicable and non-communicable diseases. This typically involves a comparison between the economic costs and health impacts of different health interventions to understand which intervention(s) are most cost-effective to use in practice.
A Health Economist at MORU MAEMOD’s Neglected Tropical Diseases Modeling (NTDM) Group since 2022, Chris’ current work focusses on: (ACORN) A Clinically Oriented antimicrobial Resistance Network; the ACT-South Asia (Azithromycin and Cefixime treatment of typhoid in South Asia) trial; and working with LOMWRU, MORU’s Lao PDR Unit, on the newly formed Unit for Health Evidence and Policy (UHEP) in Vientiane.
Chris’ ongoing research interests include antimicrobial resistance (AMR); COVID-19; Hepatitis C virus; and health economics and health technology assessment methods and institutionalising these methods in low- and middle-income countries (LMICs)
Holder of both an MSc and a BSc Economics from the University of Manchester, prior to MORU Chris worked as a health economist in the UK private sector and as an Overseas Development Institute Fellow (2019-2022) at the Health Intervention and Technology Assessment Program (HITAP) in Thailand’s Ministry of Public Health.